title: Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.
abstract: Gain of the long arm of chromosome 8 (8q) is one of the most common gains found in the advanced prostate cancer by comparative genomic hybridization. We have previously identified a putative target gene for the 8q gain, EIF3S3, that encodes a p40 subunit of eukaryotic translation initiation factor 3 (eIF3). Here, we studied the frequency of the EIF3S3 amplification in different stages of prostate cancer and co-amplification of EIF3S3 and oncogene MYC. In addition, prognostic utility of the EIF3S3 copy number alteration was evaluated. The analyses were done with fluorescence in situ hybridization and tissue microarray technology. High-level amplification of EIF3S3 was found in 11 of 125 (9%) of pT1/pT2 tumors, 12 of 44 (27%) of pT3/pT4 tumors, and 8 of 37 (22%) of lymph node metastases as well as in 26 of 78 (33%) and 15 of 30 (50%) of hormone refractory locally recurrent tumors and metastases, respectively. The amplification was associated with high Gleason score (P < 0.001). One of the 79 tumors with EIF3S3 amplification had only two copies of MYC, whereas all tumors with amplification of MYC had also amplification of EIF3S3 indicating common co-amplification of the genes. Gain of EIF3S3 was associated with poor cancer-specific survival in incidentally found prostate carcinomas (P = 0.023). In the analyses of prostatectomy-treated patients, the amplification was not statistically significantly associated with progression-free time. In conclusion, amplification of EIF3S3 gene is common in late-stage prostate cancer suggesting that it may be functionally involved in the progression of the disease.
authors.affiliation: Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Tampere, Finland.
authors.forename: O
authors.initials: O
authors.lastname: Saramäki
authors.forename: N
authors.initials: N
authors.lastname: Willi
authors.forename: O
authors.initials: O
authors.lastname: Bratt
authors.forename: T C
authors.initials: TC
authors.lastname: Gasser
authors.forename: P
authors.initials: P
authors.lastname: Koivisto
authors.forename: N N
authors.initials: NN
authors.lastname: Nupponen
authors.forename: L
authors.initials: L
authors.lastname: Bubendorf
authors.forename: T
authors.initials: T
authors.lastname: Visakorpi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D039621:Eukaryotic Initiation Factor-3; D005784:Gene Amplification; D018628:Gene Dosage; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010448:Peptide Initiation Factors / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D039621:Eukaryotic Initiation Factor-3; D010448:Peptide Initiation Factors